加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$3.17
−US$0.20 · -5.93%
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
前收盘价
US$3.17
−US$0.20 · -5.93%
盘后
US$3.23
+US$0.06 · +1.89%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
日内区间
当前US$3.17
52周区间
当前US$3.17
盘中时间采用ET。市场数据可能有所延迟。
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
日内区间
当前US$3.17
52周区间
当前US$3.17
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 405.5万 USD | 188.1万 USD | 150.3万 USD | 95.8万 USD | 219.8万 USD |
| 销货成本 | 386.5万 USD | 114.1万 USD | 109万 USD | 97.6万 USD | 77.8万 USD |
| 毛利 | 19万 USD | 74万 USD | 41.3万 USD | −1.8万 USD | 142万 USD |
| 研究与开发 | 1590万 USD | 983.9万 USD | 929.4万 USD | 730.1万 USD | 503.5万 USD |
| 销售、一般及管理费用 | 1697.6万 USD | 1378.5万 USD | 1328.5万 USD | 2153.3万 USD | 2039.2万 USD |
| 营业费用 | 3076.8万 USD | 6178.1万 USD | 2554.9万 USD | 1797.9万 USD | 5514.5万 USD |
| 利息支出 | 10.9万 USD | 8.4万 USD | 5.2万 USD | 8.3万 USD | 20.9万 USD |
| 折旧和摊销 | 219.7万 USD | 156.4万 USD | 168万 USD | 522万 USD | 420.5万 USD |
| 营业利润 | −3057.8万 USD | −6104.1万 USD | −2513.6万 USD | −1799.7万 USD | −5372.5万 USD |
| 净利润 | −5022.2万 USD | −6066.3万 USD | −2778.1万 USD | −7290.2万 USD | −6409.7万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
